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ABSTRACT 
3D printing was used as a novel medicine formulation technique for production of viable tablets 
capable of satisfying regulatory tests and matching the release of standard commercial tablets. 
Hydroxypropyl methylcellulose (HPMC 2208) (Methocel™ K100M Premium) and poly (acrylic acid) 
(PAA) (carbopol® 974P NF) were used as a hydrophilic matrix for sustained release (SR) layer. 
Hypromellose® (HPMC 2910) was used as a binder while microcrystalline cellulose (MCC) 
(Pharmacel® 102) and sodium starch glycolate (SSG) (Primojel®) were used as disintegrants for 
immediate release (IR) layer. Guaifenesin Bi-layer Tablets (GBT) were used as a model drug 
(Mucinex®) for this study. There was a favourable comparison of release of the active guaifenesin 
from the printed hydrophilic matrix compared with the commercially available GBT. The printed 
formulations were also evaluated for physical and mechanical properties such as weight variation, 
friability, hardness and thickness as a comparison to the commercial tablet and were within acceptable 
range as defined by the international standards stated in the United States Pharmacopeia (USP). All 
formulations (standard tablets and 3D printed tablets) showed n values between 0.27-0.44 which 
indicates Fickian diffusion drug release through a hydrated HPMC gel layer. 
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1. Introduction 
    It is widely believed that a key factor for future improvements in disease treatment will be driven 
by point-of-care and home-based diagnostics linked with genetic testing and emerging technologies 
such as proteomics and metabolomics analysis (Malandrino and Smith, 2011). This has led to the 
concept of personalized medicine, which foresees the customization of healthcare to an individual 
patient (Holmes et al., 2010; Scoutaris et al., 2011). However, how are the requisite ‘unique’ 
medicines for each patient to be manufactured on a routine basis? Currently no viable method used in 
manufacturing of solid dosage forms, such as tablets, is suitable. Tablets for oral administration are by 
far the most common dosage form, and are generally prepared by either single or multiple 
compressions (and in certain cases with molding) processes (Sastry et al., 2000; Jivraj et al., 2000; 
Rosca and Vergnaud, 2008). This popularity is essentially because of their ease of manufacture, good 
patient compliance, pain avoidance (compared to injection), and accurate dosing (Sastry et al., 2000; 
Jivraj et al., 2000). Powders are prepared for tablet compression via many well-established unit 
processes such as milling, mixing and granulation (dry and wet) (Parmar and Rane, 2009; Davies, 
2009). Each one of these steps can introduce difficulties in the manufacture of a medicine (e.g., drug 
degradation and form change), leading to possible batch failures and problems in optimization of 
formulations (Price et al., 2002; Surana et al., 2003; Taylor and Zografi, 1998; Yoshioka and Stella, 
2000). Tablets are almost universally manufactured at large centralized plants via these processes 
using tablet presses essentially unchanged in concept for well over a century. This route to 
manufacture is clearly unsuited to personalized medicine and in addition provides stringent 
restrictions on the complexity achievable in the dosage form (e.g., multiple release profiles and 
geometries) and requires the development of dosage forms with proven long-term stability (Scoutaris 
et al., 2011). We have previously demonstrated the use of ink-jet printing for the production of a 
formulation in a 2D array of small deposits containing the poorly soluble drug felodipine, an 
antihypertensive, with polyvinylpirrolidone (PVP) as an excipient (Scoutaris et al., 2011; Scoutaris et 
al., 2012). And also the actives captopril and thiazide (both are diuretics) with poly (lactic-co-glycolic 
acid) to mimic its commercial formulation (Capozide®) at much reduced dosages (Scoutaris, Ph.D. 
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Thesis, 2011). In these cases the drug release was altered through control of the drug loading in the 
printed spots or the inclusion of excipients that slowed release. It was proposed that this demonstrated 
the potential of this approach to print practical dosage forms (e.g., as an array of many thousands of 
spots with different release profiles and different drugs) (Scoutaris et al., 2011). However, this work 
was based on an array of micro-deposits, limiting the dosage that could be achieved and hence 
confining this approach to only the most active drugs.  
    Previous research by other workers has also shown that printed formulations are a potential route to 
personalized medicines. Sandler et al employed inkjet printing to deposit caffeine, theophylline and 
paracetamol onto a variety of surfaces (including paper) (Sandler et al., 2011). However, the amounts 
of drug deposited were small, with a maximum of 270 µg of drug deposited. For comparison, typical 
drug loadings in tablets are of the order of 500 mg (e.g. paracetamol, aspirin, and ibuprofen) (Sandler 
et al., 2011). In addition, Katstra et al., Yu et al. and Rowe et al. imported a complex multistep 3D 
printing process to produce a solid dosage forms (Rowe et al, 1999; Katstra et al., 2000; Yu et al., 
2009). To address the issues of low drug loading in 2D printed formulations and complexity in 3D 
printing process, we used a single step 3D printing process using a low cost (less than $ 1000) desktop 
3D printer to produce viable tablets capable of sustained release. This approach has the potential for 
producing medicines which would allow patients to be given an accurate and personalized treatment 
regime, which could include multiple active ingredients, either as a single blend or potentially as 
layers in a multi-layer printed tablet. For example, in the future patients suffering from chronic 
diseases such as cancer and kidney failure could have their treatment and dosage determined using 
identified genetic markers. Their individual, personalized medicines could potentially then be 
manufactured for them at the point of care. Patients would be administered an accurate and 
personalized dose given in a single tablet which may otherwise be a challenge using conventional 
centralized tableting processes (Kommanaboyina and Rhodes, 1999). Furthermore, 3D printers would 
eliminate the previously identified problematic unit processes used in the tablet production process. 
This could be important for many drugs, for example 1,2,3-trinitroxypropane (nitroglycerin), a drug 
used to treat angina pectoris, is among many noted for its tendency to degrade on storage but if 
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produced for immediate use this issue is reduced in significance (Kommanaboyina and Rhodes, 
1999).  
      For our 3D printing approach, we aim for the first time to demonstrate the 3D pharmaceutical 
printing principle by producing a printed tablet using excipients selected based on their potential to 
mimic the commercially available dosage form in terms of drug release profile. The printer employed 
is a room-temperature extrusion system, therefore feedstock for printing took the form of a viscous 
paste.  
2 Materials and methods 
2.1. Materials 
    Guaifenesin and hydrochloric acid (HCL) 37 % Ph. Eur., were purchased from VWR international 
Ltd. (Leicestershire, UK). Trisodium phosphate dodecahydrate (TSP.12 H2O) and hydroxypropyl 
methylcelloluse (HPMC 2910) (hypromellose®) were supplied by Sigma-Aldrich (Gillingham, UK). 
Poly (acrylic acid) (PAA) (Carbopol® 974P NF), hydroxypropyl methylcelloluse (HPMC 2208) 
(Methocel™ K100M Premium) were obtained as a gratis from Surfachem Group Ltd. (Leeds, UK), 
and Colorcon Limited (Dartford Kent, UK), respectively. Microcrystalline cellulose (MCC) 
(Pharmacel® 102) and sodium starch glycolate (SSG) (Primojel®) were kindly supplied as a gift from 
DFE Pharma. Guaifenesin Bi-layer Tablets (GBT) (Mucinex®) were purchased from Reckitt 
Benckiser Group (Berkshire, UK). 
2.2. Methods  
2.2.1. Printing of guaifenesin tablets 
2.2.1.1. Preparation of hydroxypropyl methylcellulose gel 
    Two HPMC gels were prepared using different viscosity grades of HPMC; HPMC 2910 (1 % w/v) 
for the immediate release (IR) layer and HPMC 2208 (1 % w/v) for the sustained release (SR) layer. 
The following steps were used to prepare HPMC 2910 gel (Fig. 1). 1 g of HPMC 2910 powder was 
added into 30 ml of hot water (90 °C) and thoroughly mixed until a good dispersion was formed. 70 g 
of ice or cold water was added and stirred for half an hour to increase polymer solubility. The gel was 
stored in a refrigerator for 24 hrs until a smooth homogenous gel with good consistency, free from air 
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bubbles and aggregates was formed (Abd-Allah et al., 2010). The other gel, HPMC 2208 (1 % w/v), 
was prepared using the same above method. 
 
Fig.1. Schematic diagram of dispersion technique of hydroxypropyl methylcelloluse powder (HPMC 2910 and 
HPMC 2208). 
2.2.1.2. Preparation of guaifenesin paste 
    The guaifenesin powder and required excipients for the IR layer (SSG and MCC) were mixed for 
30 minutes. HPMC 2910 (1 % w/v) was used as a binder for the powder blend. A pre-adjusted volume 
of HPMC 2910 gel was added and mixed until homogenous paste without aggregates and separation 
was observed. For the SR layer, different excipients (HPMC 2208 at different percentages and PAA) 
were mixed with guaifenesin powder. HPMC 2208 (1 % w/v) was used as a binder to hold up the 
ingredients together and form guaifenesin paste. Each prepared paste was filled in a separate syringe 
tool and from the software (FabStudio), GBT were extruded through a 1.2 mm nozzles using desktop 
3D printer. The IR functionality was studied using different disintegrants; MCC and SSG. The 
sustained release functionality was investigated using a hydrophilic matrix; HPMC 2208 and PAA, at 
four different HPMC 2208 percentages; GBT-HPMC (6 % w/w), GBT-HPMC (8 % w/w), GBT-
HPMC (10 % w/w) and GBT-HPMC (14 % w/w) according to the formula shown in Tables 1& 2. 
Table 1. The percentage composition of various ingredients in guaifenesin immediate release (IR) feed stock. 
 
Ingredients  (% w/w) per IR layer 
 
Guaifenesin (active ingredient ) 81 
HPMC 2910 (binder ) 2 
SSG type A (disintegrant) 7 
MCC PH 102 (disintegrant) 10 
 
6 
 
Table 2. The percentage composition of various ingredients in guaifenesin sustained release (SR) feed stock. 
Ingredients GBT-HPMC 
(6 % w/w) 
 
GBT-HPMC 
(8 % w/w) 
 
GBT-HPMC 
(10 % w/w) 
 
GBT-HPMC 
(14 % w/w) 
 
Guaifenesin (active ingredient ) 91 88 86 82 
HPMC 2208 (hydrophilic matrix) 6 8 10 14 
HPMC 2208 (binder) 2 2 2 2 
PAA (hydrophilic matrix) 2 2 2 2 
 
2.2.1.3. 3D based extrusion printer 
    To investigate the potential applicability of this concept an easily available desktop extrusion based 
3D printer (Fab@Home) (Fig. 2 a& b) was used to formulate various sustained release (SR) 
guaifenesin bilayer tablets (GBT) containing the active guaifenesin, an expectorant used in the 
treatment of respiratory tract infections, and a range of excipients (Fig. 2 c). As a realistic model 
system, we chose to try to mimic the drug release of a commercial preparation of guaifenesin. It is 
available commercially as a bi-layer tablet (containing 600 mg guaifenesin), with IR and SR layers, in 
order to provide a rapid alleviation of symptoms via the burst release, while maintaining therapeutic 
levels of drug release over an extended time-scale. 
 
2.2.2. In vitro drug release 
    In vitro drug release studies of commercial GBT (the IR layer composed of 100 mg guaifenesin, 
SSG, magnesium stearate and MCC, the SR layer composed of 500 mg guaifenesin, carbomer 934P 
NF, FD&C blue No. 1 aluminium lake, hypromellose, USP, magnesium stearate NF) and 3D printed 
tablets were performed using a United States Pharmacopeial Convention (USP) Type I apparatus at 50 
rpm (Dissolution-Erweka Dt600 Dissolution Tester) in acidic medium for 2 hrs (representative of the 
stomach) followed by addition of 0.2 M trisodium phosphate dodecahydrate (TSP.12 H2O) solution to 
increase the pH to 6.8, for 10 hrs (representative of the small intestine) to mimic the gastrointestinal 
fluid pH. 6 tablets from each formulation were placed in acidic dissolution medium 675 ml of 0.1 M 
hydrochloric acid. 5.0 ml samples were withdrawn at 0.25, 0.5, 1, and 2 hrs time interval from each 
vessel (Blume et al., 2002). 225 ml of 0.2 M TSP.12H2O was added to each vessel immediately after 
two hours to raise the solution pH 6.8 (Blume et al., 2002). The pH was adjusted by adding few drops 
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of 2.0 M HCl. 5.0 ml samples were subsequently removed at 4, 6, 8, 10 and 12 hrs. The dissolution 
samples were filtered using standard 20 μm filters (Copley Scientific, UK). 1 ml from each 5 ml 
sample was diluted by 9 ml of a suitable dissolution medium and analyzed with UV-Visible 
spectrophotometer (Cecil UV, Nottingham, UK) at a λmax of 274 nm. The temperature of the 
dissolution medium was retained at 37 °C ± 0.5 ºC throughout the test. Two guaifenesin calibration 
curves were prepared using acidic medium (0.1 M HCl) and a phosphate buffer medium (pH 6.8) and 
used to identify concentration of unknown samples (Fig. S.1).   
 
Fig. 2. (a) Photograph and (b) schematic diagram of the Fab@Home printer model 2. (c) Images at different 
scales of 3D printer produced guaifenesin bilayer tablets (H/W/L = 7 × 6.3 × 15.5 mm) and commercial GBT 
(H/W/L = 5.91 × 9.6 × 16.4 mm). (ii) Top view and (iii) underside view of commercial GBT. (iv) & (v) Gel 
barrier surrounding commercial GBT and 3D printed bilayer tablet after 2 hrs dissolution test, respectively. (vi) 
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Top view (vii) side view & (viii) underside view of individual 3D printed bilayer tablets. The scale bar (ii-viii) 
is 10 mm. 
 
2.2.3. Physical characterization of guaifenesin tablets 
2.2.3.1. Weight uniformity test 
    20 tablets were individually weighed and their average was calculated and compared with 
percentage of weight variation (Bushra et al., 2008; Remington and Beringer, 2006). 
2.2.3.2. Hardness  
    Ideal tablets should have enough hardness to resist breaking during transportation, storage. 
However, tablets also should be soft enough to disintegrate and release drug (US Pharmacopoeia 
XXIV, 2000). 6 tablets were randomly selected and tested for hardness using hardness tester 
(Hardness tester C50, I Holland Ltd., Holland) (US Pharmacopoeia XXIV, 2000; Bushra et al., 2008). 
2.2.3.3. Friability 
    20 guaifenesin tablets from each formulation were selected randomly and placed on a sieve. The 
loose dust found over tablets was removed with a soft brush. The tablets were accurately weighed. 
The tablets were placed in a friabilator (Friability tester, E-1851 Erweka) and rotated at a constant 
speed of 25 rpm for a period of 4 min (Bushra et al., 2008; Remington and Beringer, 2006; Folttmann 
and Quadir, 2008). The tablets were cleaned from loose dust and reweighed and the percentage weight 
loss calculated. 
 
3. Results and discussion 
3.1. Dissolution profiles 
    The dissolution data presented in Fig. 3 shows that all formulations displayed sustained release of 
guaifenesin over a period of 12 hrs as is required. An initial burst release (> 20 % in half an hour) of 
guaifenesin occurred from the IR layer of the formulations. This initial high amount of guaifenesin is 
attributed to the inclusion of the disintegrants; MCC and SSG. Disintegrants are designed to cause 
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tablets to break up on exposure to water and rapidly release any active ingredients. The initial release 
of guaifenesin from the formulations with low concentration of HPMC 2208 in GBT-HPMC (6 % 
w/w) and GBT-HPMC (8 % w/w) was high (> 75 % in two hours) compared to the drug release (65 % 
in two hours) and (57 % in two hours) from GBT-HPMC (10 % w/w) and GBT-HPMC (14 % w/w), 
respectively. This is mainly because of release of guaifenesin from the IR layer and also drug release 
from the surface of SR layer due to the small channels found underside of individual 3D printed 
bilayer tablets (Fig. 2c (viii)). The drug release of guaifenesin from GBT-HPMC (14 % w/w) was the 
closest to the commercial GBT. This is consistent with the increased amount of hydrophilic matrix 
material used (HPMC 2208) (14 % w/w). Finally, the release rate of guaifenesin release decreased as 
the concentration of HPMC 2208 was increased. This increase in concentration of HPMC is expected 
to lead to improved wettability, enhanced water uptake and greater swelling of the hydrophilic matrix 
and gel barrier formation which is all consistent with the observed reduction in drug release rate from 
the formulation with greater amounts of HPMC 2208 (Fig. 2c (iv & v)) and (Fig. S.2) (Folttmann and 
Quadir, 2008). 
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Fig. 3. Dissolution profile of guaifenesin tablets; GBT-HPMC (6 % w/w), GBT-HPMC (8 % w/w), GBT-HPMC 
(10 % w/w), GBT-HPMC (14 % w/w) and commercial GBT. The error bars are the standard error in the mean 
where n = 6.  
3.2. Mechanical properties  
    The tablets were evaluated for weight variation, thickness, hardness and friability and all tablets 
complied with USP specifications (total weight loss is ≤ 1 % for friability, % deviation = ± 5 % for 
weight variation) (US Pharmacopoeia XXIV, 2000). The results of these standard pharmacopeial tests 
are presented in Fig. 4 (i to iv). The weight variations of the five formulations are shown in Fig. 4 (i). 
Although the absolute weights of the different formulations vary slightly between formulations, all 
tablets weight are from 650-730 mg, which is typical for many commercial bilayer formulations. The 
variation in tablet thickness is presented in Fig. 4 (ii). All formulations (commercial and printed) have 
similar average thicknesses. GBT-HPMC (6 % w/w) (printed) has by far the highest in-batch variation 
in thickness. The commercial formulation exhibited the narrowest variation in thickness, and this is in 
itself not unreasonable. Our 3D printing process is an experimental approach and is not expected at 
this stage to reproduce the very small variations seen in formulations manufactured using well-
established tableting technology. The key point perhaps is that changing the formulation type for the 
3D printed tablets allows a level of control to be achieved over the variation in thickness. The tablet 
hardnesses are shown in Fig. 4 (iii). The hardness of commercial GBT is more than twice that of the 
printed ones. Considering the nature of the manufacturing processes for the commercial (high 
pressure compression) versus the printed tablets, this difference seems entirely reasonable. With 
respect to the lower hardness exhibited by the 3D printed tablets, it should be noted that all the printed 
tablets can be handled readily without any loss of structural integrity. The parameter for which there is 
the greatest difference between commercial and printed tablets is the friability (Fig. 4 (iv)). This 
variation in friability (% in weight loss) was attributed to the low percentage of binder, low-viscosity 
grade HPMC 2910 (1 % w/w) in the IR layer, a binding agent which gives reasonable binding 
strength between active and non-active ingredients and form tablets with good mechanical properties 
(Nagadivya et al., 2012). However, the friability of GBT-HPMC (14 % w/w) was the closest to the 
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commercial GBT. The % in weight loss can be decreased by increasing the binder percentage which 
will also decrease the burst release of drug from the IR layer and decrease the overall drug release for 
the whole tablet and eventually shift the drug release rate to mimic the commercial GBT. From a 
subjective and qualitative assessment, the printed tablets appear to be quite robust and are able to 
withstand a reasonable amount of rough handling, including dropping onto a wooden table top from a 
height of six inches.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Box plot summery of weight variation (mg) (i), thickness (mm) (ii), hardness (kg cm-2) (iii) and friability 
(%) (iv) for GBT-HPMC (6 % w/w), GBT-HPMC (8 % w/w), GBT-HPMC (10 % w/w), GBT-HPMC (14 % w/w) 
and commercial GBT. 
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3.3. Drug release kinetics  
    Finally, so as to understand the drug release mechanisms displayed by the formulations, the modes 
of release of guaifenesin at acidic conditions (0-2 hrs), buffer conditions (2-12 hrs) and for both 
conditions (0-12 hrs) were modeled (Folttmann and Quadir, 2008; Patra et al., 2007; Pattanayak et al., 
2011). For all formulations, the "best fit" model remained the same, irrespective of the dissolution 
conditions (Table S.1). The commercial GBT was best fitted by the Higuchi equation (i.e., cumulative 
percentage drug release is proportional to the square root of time) with an r2 value of 0.99 and an n 
value of 0.44. This suggests that the drug is released primarily by diffusion through the hydrated 
HPMC gel layer for these formulations (Dash et al., 2010; Nep et al., 2010). GBT-HPMC (10 % w/w) 
and GBT-HPMC (14 % w/w) were best modeled using the Korsmeyer–Peppas model, Eqn. 1: 
 
 Mt M∞⁄ = Kt
n                                                                       (1) 
 
Where Mt / M∞ is the fraction of drug released at time t, K is the release rate constant and n the release 
exponent (Dash et al., 2010). They showed an n values of 0.29 and 0.32 fitted (r2 = 0.99) which 
indicate Fickian diffusion, respectively (Grassi and Grassi, 2005). GBT-HPMC (6 % w/w) and GBT-
HPMC (8 % w/w) displayed Fickian diffusion having the same n value (0.27) and fitted (r2 = 0.97) 
and (r2 = 0.94), respectively. They were best modeled using the first order model (i.e., log cumulative 
percentage of drug remaining vs. time) where the drug release rate depends on its concentration (Dash 
et al., 2010). Overall, all formulations showed n values between 0.27-0.44 which that indicates 
Fickian diffusion drug release through the hydrated HPMC gel layer dominates for these formulations 
(Fig. S.3). 
 
4. Conclusions 
    In this summary, we have demonstrated the production of relatively complex formulations printed 
into bilayer tablets using an inexpensive desktop 3D printer that can match the release of a 
commercial GBT (manufactured using conventional tablet compression methods). We believe that 
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there is clear potential for 3D printing to allow entirely new formulation types, such as new 
geometries, complex multi-layer or multi-reservoir tablets, and others. The potential for using 3D 
printing to develop new ways to treat many chronic conditions (e.g. asthma, arthritis and diabetes) is 
exciting. We believe that the present work is a significant step towards the demonstration and 
validation of simple, low-cost 3D printing for the tailored manufacture of medicines, which has the 
potential to play a crucial role in future developments in personalized care and treatment. 
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